Skip to main
  1. Stocks
  2. Aurinia Pharmaceuticals
  3. Forecast
AUPH

Aurinia Pharmaceuticals (AUPH) Stock Forecast & Price Target

Aurinia Pharmaceuticals (AUPH) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 0%
Hold 67%
Sell 0%
Strong Sell 0%

Bulls say

Aurinia Pharmaceuticals is attractive because LUPKYNIS continues to deliver durable commercial growth, with Q3/26 net product sales of $79.4MM up 12% y/y and 2026 product sales guidance raised to $310–315MM, while total revenue guidance increased to $325–330MM. Its fundamentals are further supported by strong profitability and liquidity, as Q3/26 net income was about $31.7MM, cash and investments reached roughly $486.9MM, and operating cash flow remained solid at $46.4MM. Beyond the base business, the under-penetrated lupus nephritis market, the ~41% renal response seen in Phase III, and aritinercept progressing across four indications create additional long-term growth optionality, while favorable legal developments around exclusivity improve the durability of earnings power.

Bears say

Aurinia Pharmaceuticals is viewed negatively because its valuation is heavily dependent on LUPKYNIS, while the pipeline is thin with aritinercept still in early clinical development and no disclosed near-term catalyst strong enough to offset core product risk. Patent litigation remains a major overhang, with seven to eight generic filers challenging exclusivity and a proposed bench trial in early 2028, creating a meaningful chance of generic erosion as soon as mid-2028 or even 2027 in downside cases. Adoption and competition risks further pressure the outlook, as slower-than-expected penetration and new lupus nephritis therapies from better-resourced large pharma could erode sales and leave little value in the downside scenario beyond LUPKYNIS.

Aurinia Pharmaceuticals (AUPH) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 0% recommend Buy, 67% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aurinia Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Aurinia Pharmaceuticals (AUPH) Analyst Forecast & Price Prediction

Get the latest Aurinia Pharmaceuticals (AUPH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Aurinia Pharmaceuticals (AUPH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aurinia Pharmaceuticals (AUPH) Forecast

Analysts have given Aurinia Pharmaceuticals (AUPH) a Buy based on their latest research and market trends.

According to 3 analysts, Aurinia Pharmaceuticals (AUPH) has a Buy consensus rating as of Nov 21, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aurinia Pharmaceuticals (AUPH)


Aurinia Pharmaceuticals (AUPH) Analyst Forecast & Price Prediction

Get the latest Aurinia Pharmaceuticals (AUPH) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Aurinia Pharmaceuticals (AUPH)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AUPH stock data and trends